Cervical Dysplasia and Human Papillomavirus in Women of the Republic of Sakha (Yakutia)

ORIGINAL ARTICLE
Maria P. Kirillina, Irina V. Kononova, Sargylana I. Sofronova, Matrena N. Mikhailova, Varvara A. Vorontsova, Elena L. Lushnikova

 
International Journal of Biomedicine. 2020;10(2):165-168.
DOI: 10.21103/Article10(2)_OA16
Originally published June 15, 2020.

Abstract: 

The purpose of this study was to investigate the relation between the presence of cervical dysplasia and HPV infection in women of the Republic of Sakha (Yakutia) (RS(Y)), to analyze cytological samples for detecting the presence of pathology and the degree of cervical dysplasia, and to detect the level of HPV infection, and establish the dependence of HPV-test positivity on the presence of dysplasia and the woman’s age.
Methods and Results: Cytological material was taken from cervix uteri and cervical canal scraping from 100 patients aged between 22 and 60 years (mean age of 38.9±9.2 years).  The sample from every patient was obtained by traditional cytology and liquid-based cytology (LBC) on the automated system CellPrep Plus (Korea).  The results of LBC were interpreted under the terminology system of the Bethesda System (2015). HPV detection and typing (types 6, 11, 44, 16, 18, 26, 31, 33, 35, 39, 45, 51, 52, 53, 56, 58, 59, 66, 68, 73, 82) were performed by real-time PCR using commercial test systems according to their instructions.
The analysis of cytological samples by the LBC method in women of RS(Y) revealed a high prevalence of NILM in the samples to compare with intraepithelial lesions of the cervix. Among intraepithelial lesions, LSIL was significantly more common. Positive HPV tests were observed in less than half of the cases. The vast majority of positive HPV tests were high–risk HPV types, and 16 and 51 types marked the most frequent. The positive tests for high–risk HPV types in women with NILM and intraepithelial lesions (LSIL, HSIL, ASCUS) were approximately equal. The frequency of positive tests for high–risk HPV types in women under 45 was higher than in women 46 years and older.
Conclusion: The combined use of LBC and HPV testing for high–risk HPV infection improves the effectiveness of diagnostics by reducing the amount of uninformative material and allows detecting pathological changes at an earlier stage.

Keywords: 
human papillomavirus • cervical cancer • liquid-based cytology • squamous intraepithelial lesion
References: 
  1. Zubritsky MG, Yakoltsevich MI, Tingaeva ER, Aniskevich AA, Lazarevich NA, Basinskiy VA. [Human papillomavirus and cervical cancer]. Journal of the Grodno State Medical University. 2009;(1):18-22. [Article in Russian].
  2. Wheeler CM, Hunt WC, Schiffman M, Castle PE; Atypical Squamous Cells of Undetermined Significance/Low-Grade Squamous Intraepithelial Lesions Triage Study Group. Human papillomavirus genotypes and the cumulative 2-year risk of cervical precancer. J Infect Dis. 2006;194(9):1291‐1299. doi:10.1086/507909
  3. Liu Y, Pan Y, Gao W, Ke Y, Lu Z. Whole-Genome Analysis of Human Papillomavirus Types 16, 18, and 58 Isolated from Cervical Precancer and Cancer Samples in Chinese Women. Sci Rep. 2017;7(1):263. Published 2017 Mar 21. doi:10.1038/s41598-017-00364-9
  4. Bernard HU, Burk RD, Chen Z, van Doorslaer K, zur Hausen H, de Villiers EM. Classification of papillomaviruses (PVs) based on 189 PV types and proposal of taxonomic amendments. Virology. 2010;401(1):70‐79. doi:10.1016/j.virol.2010.02.002
  5. Rogovskaya SI. Papillomavirus infection in women and cervical pathology: to help a practitioner. 2nd ed. M.: GEOTAR-Media; 2008. [In Russian].
  6. Prilepskaya VN, Bayramova GR, Kogan EA, Chernova VF, Okushko AA. [New opportunities for early diagnosis and prevention of HPV-associated cervical lesions]. МС. 2015. №XX. URL: https://cyberleninka.ru/article/n/novye-vozmozhnosti-ranney-diagnostiki-... [Article in Russian].
  7. Li N, Franceschi S, Howell-Jones R, Snijders PJ, Clifford GM. Human papillomavirus type distribution in 30,848 invasive cervical cancers worldwide: Variation by geographical region, histological type and year of publication. Int J Cancer. 2011;128(4):927‐935. doi:10.1002/ijc.25396
  8. Burk RD, Chen Z, Van Doorslaer K. Human papillomaviruses: genetic basis of carcinogenicity. Public Health Genomics. 2009;12(5-6):281‐290. doi:10.1159/000214919
  9.  Smith JS, Lindsay L, Hoots B, et al. Human papillomavirus type distribution in invasive cervical cancer and high-grade cervical lesions: a meta-analysis update. Int J Cancer. 2007;121(3):621‐632. doi:10.1002/ijc.22527
  10. Gudz OV, Kamilova IK, Miklin OP. [HPV infection of the cervix uteri: Prospects for combination treatment]. Russian Bulletin of Obstetrician-Gynecologist. 2016;(2):99-103. [Article in Russian].
  11. Novik VI. Epidemiology of cervical cancer, risk factors, screening. Practical Oncology. 2002;3(3):156-165. [Article in Russian].
  12. Kedzja W. Analiza czynnikow komorkowych i ustrojowych w procese kancerogenezy komorek nablonka paraepidermalnego szyjki macicy zakazonych wirusem brodawczaka ludzskego. Poznan: Wydawnictwo Naukowe; 2003.
  13. Shabalova IP. Cytological atlas. Criteria for the diagnosis of cervical diseases. M.: Triad-X; 2001.
  14. Zaravinos A, Mammas IN, Sourvinos G, Spandidos DA. Molecular detection methods of human papillomavirus (HPV). Int J Biol Markers. 2009;24(4):215‐222. doi:10.5301/jbm.2010.754
  15. Dobrokhotova YuE, Venediktova MG, Sarantsev AN, Morozova KV, Suvorova VA. [A modern approach to the treatment of moderate to severe cervical dysplasia against the background of human papillomavirus using antiviral therapy]. Lechebnoe Delo. 2016;(4). URL: https://cyberleninka.ru/article/n/sovremennyy-podhod-k-lecheniyu-displaz... [Article in Russian].
  16. Sherman ME, Lorincz AT, Scott DR, et al. Baseline cytology, human papillomavirus testing, and risk for cervical neoplasia: a 10-year cohort analysis. J Natl Cancer Inst. 2003;95(1):46‐52. doi:10.1093/jnci/95.1.46
  17. Hoyer H, Scheungraber C, Kuehne-Heid R, et al. Cumulative 5-year diagnoses of CIN2, CIN3 or cervical cancer after concurrent high-risk HPV and cytology testing in a primary screening setting. Int J Cancer. 2005;116(1):136‐143. doi:10.1002/ijc.20955
  18. Petry KU, Menton S, Menton M, et al. Inclusion of HPV testing in routine cervical cancer screening for women above 29 years in Germany: results for 8466 patients. Br J Cancer. 2003;88(10):1570‐1577. doi:10.1038/sj.bjc.6600918
  19. The Bethesda System for Reporting Cervical Cytology: Definitions, Criteria, and Explanatory Notes. 3rd Edition. Nayar R, Wilbur David C, editors. Springer International Publishing Switzerland; 2015.
  20. Krasnopolsky VI, Serova OF, Tumanova VA, Zarochentseva NV, Melnik TN,  Lipovenko LN, Pozdnyakova TI. [Impact of infections on the female reproductive system].  Russian Bulletin of Obstetrician-Gynecologist. 2004;4(5):26-29. [Article in Russian].

Download Article
Received May 5, 2020.
Accepted June 2, 2020.
©2020 International Medical Research and Development Corporation.